how to withdraw in lol646
U.S. stock indexes reached more records after tech companies talked up how much artificial intelligence is boosting their results. The S&P 500 climbed 0.6% Wednesday to add to what looks to be one of its best years of the millennium. The Dow Jones Industrial Average gained 0.7%, while the Nasdaq composite added 1.3% to its own record. Salesforce pulled the market higher after highlighting its artificial-intelligence offering for customers. Marvell Technology jumped even more after saying it’s seeing strong demand from AI. Treasury yields eased, while bitcoin climbed after President-elect Donald Trump nominated a crypto advocate to head the Securities and Exchange Commission. On Wednesday: The S&P 500 rose 36.61 points, or 0.6%, to 6,086.49. The Dow Jones Industrial Average rose 308.51 points, or 0.7%, to 45,014.04. The Nasdaq composite rose 254.21 points, or 1.3%, to 19,735.12. The Russell 2000 index of smaller companies rose 10.22 points, or 0.4%, to 2,426.56. For the week: The S&P 500 is up 54.11 points, or 0.9%. The Dow is up 103.39 points, or 0.2%. The Nasdaq is up 516.95 points, or 2.7%. The Russell 2000 is down 8.16 points, or 0.3%. For the year: The S&P 500 is up 1,316.66 points, or 27.6%. The Dow is up 7,324.50 points, or 19.4%. The Nasdaq is up 4,723.76 points, or 31.5%. The Russell 2000 is up 399.49 points, or 19.7%.Mutual of America Capital Management LLC lessened its position in STERIS plc ( NYSE:STE – Free Report ) by 2.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,171 shares of the medical equipment provider’s stock after selling 318 shares during the period. Mutual of America Capital Management LLC’s holdings in STERIS were worth $2,952,000 at the end of the most recent reporting period. Other hedge funds have also recently modified their holdings of the company. Bleakley Financial Group LLC increased its holdings in STERIS by 8.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider’s stock valued at $407,000 after purchasing an additional 134 shares during the period. Assetmark Inc. increased its stake in shares of STERIS by 24.6% during the third quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider’s stock valued at $3,252,000 after buying an additional 2,647 shares during the period. BDF Gestion bought a new position in shares of STERIS during the second quarter valued at approximately $2,644,000. KBC Group NV lifted its stake in STERIS by 52.0% in the third quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider’s stock worth $2,928,000 after acquiring an additional 4,132 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in STERIS by 7.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after acquiring an additional 120,616 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock. Insiders Place Their Bets In other news, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. The trade was a 35.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Corporate insiders own 1.14% of the company’s stock. Wall Street Analysts Forecast Growth Check Out Our Latest Analysis on STE STERIS Price Performance STE stock opened at $214.34 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. The firm has a market capitalization of $21.16 billion, a price-to-earnings ratio of 48.94 and a beta of 0.85. The firm has a 50 day moving average price of $227.28 and a 200-day moving average price of $228.52. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24. STERIS ( NYSE:STE – Get Free Report ) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the previous year, the company posted $2.03 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. Equities research analysts forecast that STERIS plc will post 9.15 EPS for the current fiscal year. STERIS Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a yield of 1.06%. STERIS’s dividend payout ratio is currently 52.05%. STERIS Company Profile ( Free Report ) STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. See Also Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc ( NYSE:STE – Free Report ). Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter .
Where Will Enbridge Stock Be in 3 Years?Western Pa. experts offer tips on navigating lingering election-related tensions over holidays
The Jacksonville Jaguars placed quarterback Trevor Lawrence (concussion) on injured reserve Wednesday, likely ending his season after a vicious illegal hit in last week's loss to the Houston Texans. Lawrence, slammed in the head and neck by Texans linebacker Azeez Al-Shaair after giving himself up, would be eligible to return Week 18. However, the 2-10 Jags are already eliminated from playoff contention. Mac Jones will start for the Jags this week against the Tennessee Titans. Al-Shaair, meanwhile, was suspended three games by the NFL on Tuesday. Lawrence, 25, has thrown for 2,045 yards, 11 touchdowns and seven interceptions in 10 starts this season. He also missed time with a left (non-throwing) shoulder injury. Lawrence was carrying the ball and went into a feet-first slide at Houston's 45-yard line during the second quarter of Sunday's game. Al-Shaair launched into him and delivered a forearm shot near the quarterback's head and shoulder. Multiple skirmishes erupted as Lawrence lay prone on the field. Al-Shaair was ejected, along with Jaguars cornerback Jarrian Jones. Lawrence immediately displayed the hand motion known as the fencing posture that is associated with traumatic brain injury. However, he was able to stand after being attended to briefly, and he sat up while being taken to the locker room on a cart. Al-Shaair took to social media Monday to apologize but the NFL was unmoved, announcing the three-game suspension on Tuesday. He is appealing. Al-Shaair, 27, is a repeat offender this season, having just been fined $11,255 for a late hit on Tennessee Titans running back Tony Pollard last week. He was also fined $11,817 for punching Chicago Bears running back Roschon Johnson in a Week 2 game. That came after a sideline skirmish that began after Al-Shaair hit Bears quarterback Caleb Williams late out of bounds but wasn't flagged. Lawrence has thrown for 13,815 yards, 69 TDs and 46 INTs since being selected No. 1 overall by the Jags in the 2021 draft out of Clemson. This article first appeared on Field Level Media and was syndicated with permission.Trump picks Rep. Lori Chavez-DeRemer to lead Labor DepartmentAP Top 25: Alabama, Mississippi out of top 10 and Miami, SMU are in; Oregon remains unanimous No. 1SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR ® -SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002. "We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer's disease and remain committed in our mission to develop safe and effective treatments for the millions of people worldwide impacted by neurodegenerative diseases,” said Gary Romano, M.D., Ph.D., Chief Medical Officer at Alector. "With a robust dataset from the INVOKE-2 trial, we plan to further explore TREM2 biology. We extend our deepest gratitude to the dedicated investigators, patients and caregivers who made this important trial possible. We plan to share the results of the trial with the scientific community in the near future in the hopes of contributing to the understanding of AD pathophysiology and advancing effective therapeutics for this terrible disease.” Based upon the results, Alector is stopping the long-term extension study. Alector remains committed to advancing its mechanistically broad and genetically validated drug candidates for the treatment of neurodegenerative diseases. At the core of this effort are the company's progranulin-elevating programs, latozinemab and AL101/GSK4527226, developed in collaboration with GSK. Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a progranulin gene mutation is expected in late 2025 or early 2026. PROGRESS-AD, a global Phase 2 clinical trial evaluating AL101/GSK4527226 in early AD, has reached more than one-third of its target enrollment of 282 participants. Alector is also advancing its preclinical candidates aimed at a broad and diverse range of protein and enzyme targets. In addition to advancing its pipeline, the company is continuing to develop its proprietary and versatile blood-brain barrier technology platform, Alector Brain Carrier (ABC). ABC aims to enhance the delivery of therapeutic antibodies, proteins and enzymes, achieve deeper penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. To align resources with these strategic priorities, Alector is reducing its workforce by approximately 17%. By focusing on organizational goals, Alector continues to build upon its core strength in developing novel therapies for neurodegenerative diseases, with the potential to deliver transformative value for patients. As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call. About INVOKE-2 INVOKE-2 (Clinicaltrials.gov identifier NCT04592874), was a randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). The trial, conducted at multiple sites across 11 countries, utilized a common close design with up to 96 weeks of randomized treatment, and all participants remained on their assigned regimen until the last participant completed 48 weeks of treatment. This design provided the opportunity to capture more observations for the primary analysis, with data collected at 48, 72, and 96 weeks. Patients were randomized to three dose regimens of AL002, 15mg/kg IV/q4w, 40mg/kg IV/q4w, 60mg/kg IV/q4w, or placebo. About Alector Alector is a clinical-stage biotechnology company that has pioneered immuno-neurology. The company has discovered and is developing a portfolio of mechanistically broad and genetically validated product candidates, including antibodies, protein and enzyme replacement therapies, for neurodegenerative diseases. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Alector is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, workforce reduction, business strategy, product candidates, planned and ongoing preclinical studies and clinical trials, expected milestones, and expectations of our collaborations. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Quarterly Report on Form 10-Q filed on November 6, 2024, with the Securities and Exchange Commission ("SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law. Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected] 1AB (media) Dan Budwick 973-271-6085 [email protected] Argot Partners (investors) Laura Perry 212-600-1902 [email protected]